SCHEMBL6791609

SCHEMBL6791609

CC(C)c1ccc2c(=O)c3c(cnn3C)[nH]c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBK1 Q9UHD2 2/20 0.48
AURKA O14965 1/20 0.48
DAPK3 O43293 1/20 0.48
JAK2 O60674 1/20 0.48
MAP4K4 O95819 1/20 0.48
PAK4 O96013 1/20 0.48
ABL1 P00519 1/20 0.48
LCK P06239 1/20 0.48
FYN P06241 1/20 0.48
CSF1R P07333 1/20 0.48
RET P07949 1/20 0.48
IGF1R P08069 1/20 0.48
FLT1 P17948 1/20 0.48
LTK P29376 1/20 0.48
KDR P35968 1/20 0.48
FLT3 P36888 1/20 0.48
MAPK8 P45983 1/20 0.48
MAPK9 P45984 1/20 0.48
CLK2 P49760 1/20 0.48
GSK3A P49840 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6783202 0.81 FEN1 (0.42) CDK5KIF11PRMT5WDR77CYP17A1
SCHEMBL6785648 0.78 KIF11 (0.47) KIF11PRMT5WDR77KDM4ECDK2
SCHEMBL6786716 0.77 AURKA (0.32) TBK1AURKADAPK3JAK2MAP4K4
SCHEMBL6792539 0.76 GRIN2D (0.36) PRMT5WDR77KDM4EGRIN2DGRIN3B
SCHEMBL6787118 0.74 MPO (0.38) KDRKDM4EALDH1A1GLAGAA
SCHEMBL6781520 0.73 MEN1 (0.53) KIF11KDM4EALDH1A1GLAGAA
SCHEMBL2707231 0.73 KIF11 (0.62) TBK1AURKADAPK3JAK2MAP4K4
SCHEMBL6785518 0.73 MLKL (0.38) ALKPRMT5KDM4EALDH1A1GLA
SCHEMBL6786900 0.72 KDM4E (0.51) KIF11KDM4EALDH1A1GLAGAA
SCHEMBL15981940 0.72 KIF11 (0.81) TBK1AURKADAPK3JAK2MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6686373-B2 ANALGESICS; ANTIINFLAMMATORY AGENT WARNER-LAMBERT COMPANY LLC 2004-02-03 US disclosed
US-20030130277-A1 Pyrazoloquinolinone derivatives as protein kinase C inhibitors KAWAMURA KIYOSHI (JP) 2003-07-10 US disclosed
EP-1310498-A2 Pyrazoloquinolinone derivatives as protein kinase C inhibitors PFIZER INC. (US) 2003-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130277-A1 Pyrazoloquinolinone derivatives as protein kinase C inhibitors PRKCB, PRKCA, PRKCG TBK1 119/4885AURKA 497/4885DAPK3 133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.